Baiqu Biology Completes Nearly RMB 100 Million in Series B Financing; Qiming Venture Partners Invests Again

Baiqu Biology has completed nearly RMB 100 million in Series B financing, exclusively led by CSC Financial Capital, with follow-on investment from existing shareholder Qiming Venture Partners. The funds will be used for multi-omics + AI R&D, new product development, and capacity layout both domestically and internationally. Founded in 2013, the company has served over 70,000 projects, with an annual sample testing throughput exceeding 600,000 cases, and its business covers multiple regions at home and abroad

According to the "Science and Technology Innovation Board Daily" on the 10th, Shanghai Baiqu Biology Biomedical Technology Co., Ltd. (hereinafter referred to as "Baiqu Biology") recently completed nearly RMB 100 million in Series B financing, exclusively led by CSC Financial Capital, with continued investment from existing shareholder Qiming Venture Partners.

The proceeds from this financing are planned to be used for the R&D of multi-omics + AI for Science, the development of new products in multi-omics such as single-cell metabolomics, spatial metabolomics, single-cell proteomics, and spatial proteomics, the construction of a multi-omics + AI mass spectrometry capacity center in Zhejiang, and the layout of an overseas headquarters in Singapore and laboratories in Europe and the United States. This aims to promote the practical application of mass spectrometry-based multi-omics + AI technology in basic scientific research, biopharmaceutical R&D, and clinical medical translation globally.

Existing shareholder Qiming Venture Partners continued its investment in this round.

According to data from Cailianshe Venture Connect – Zhizhong, using October 2026 as the forecast baseline time, the probability of Shanghai Baiqu Biology Biomedical Technology Co., Ltd. securing further financing in the subsequent two years is 68.74%.

Baiqu Biology was founded in 2013 and is headquartered in Jiading District, Shanghai. It is a company focused on applying innovative mass spectrometry technology in the fields of animal and plant life sciences and medical health.

Founder Deng Junliang is committed to translating multi-omics research achievements into clinical early screening and diagnostic products to improve quality of life. The core team comes from prestigious universities such as Fudan University and the Chinese Academy of Sciences, with over ten years of deep expertise in metabolomics technology.

In its early stages, the company built a self-developed library of over 20,000 metabolite standards; it currently constructs an industry-leading metabolite standard library and a high-level technical platform, accumulating standardized biological databases and analytical methodologies. It is now proactively laying out next-generation metabolomics, single-cell, and spatial multi-omics directions, deeply integrating mass spectrometry technology with AI to support AI model training and high-depth multimodal analysis.

The company has served over 70,000 projects, with an annual sample testing throughput exceeding 600,000 cases; it serves over 3,000 institutions, including more than 360 Grade A tertiary hospitals; it has assisted partners in publishing over 3,000 articles, with an average impact factor exceeding 10; its business covers the entire country as well as overseas regions such as Singapore, Europe, and the United States, making it a professional brand in the domestic metabolomics scientific research service market.